IndustryCompany release

Quantum-Si cuts 2026 spending guidance after Q3 revenue of $212,000, keeps Proteus launch target

🇺🇸 Quantum-Si Inc (QSI) · Thu 05 Nov 2026

The protein-sequencing company reported a $22.3 million quarterly net loss, opened Proteus pre-orders and reaffirmed its cash runway into the fourth quarter of 2028.

Quantum-Si Inc reported third-quarter 2026 results on 5 November, posting revenue of $212,000 and a net loss of $22.3 million. The company said it is in the middle of its transition from the Platinum platform to Proteus, its next-generation protein-sequencing system.

Management lowered its 2026 guidance for adjusted operating expenses and cash usage. The update follows a workforce reduction of about 20% announced in August. The company reaffirmed that its cash runway extends into the fourth quarter of 2028.

Quantum-Si also launched a pre-order programme for Proteus and kept its target of a commercial launch in the second quarter of 2027. The summary available does not give pricing, pre-order volumes, technical specifications or the exact revised guidance ranges.

The company's filing was the only source for this report, and no further detail on the quarter was available at the time of writing.

What it means for your team

  • Laboratories and research groups evaluating protein-sequencing tools can now register interest in Proteus through the pre-order programme, with commercial availability targeted for Q2 2027.
  • The Platinum-to-Proteus transition is depressing revenue, so Platinum-based users may want to ask the company about product support during the changeover.
  • Market-access and procurement teams should treat the 2027 launch date as a company target rather than a confirmed timeline.

Company's press release (SEC filing): Quantum-Si Inc ↗

Article written by VigiEye from the official source (Quantum-Si Inc). Claims are the company's own. AI-assisted; check the source before acting.

More Industry All →